| Page 17 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

Significance of absolute neutrophil count before allogeneic hematopoietic stem cell transplantation in adult patients with aplastic anemia

Author(s): 
Nakamura Y, Zaimoku Y, Yamaguchi H, Yamazaki H, Kanaya M, Uchida N, Doki N, Sakurai M, Hiramoto N, Kako S, Onizuka M, Onodera K, Maruyama Y, Ohigashi H, Nishida T, Yoshihara S, Matsuoka KI, Eto T, Kanda Y, Fukuda T, Atsuta Y, Onishi Y
Primary Author: 
Nakamura Y
Journal Title: 
Annals of Hematology
Original Publication Date: 
Aug 2024

The impact of absolute neutrophil count (ANC) before allogenic hematopoietic stem cell transplantation (HSCT) on the outcomes for patients with

Bone Marrow Disease(s): 

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes

Author(s): 
Tentori CA, Gregorio C, Robin M, Gagelmann N, Gurnari C, Ball S, Caballero Berrocal JC, Lanino L, D'Amico S, Spreafico M, Maggioni G, Travaglino E, Sauta E, Meggendorfer M, Zhao LP, Campagna A; GenoMed4All, Synthema, GESMD, FISIM, and EuroBloodNET;
Primary Author: 
Tentori CA
Journal Title: 
Journal of Clinical Oncology
Original Publication Date: 
Aug 2024

Purpose: Allogeneic hematopoietic stem-cell transplantation (HSCT) is the only potentially curative treatment for patients with

Bone Marrow Disease(s): 

Kidney involvement in myelodysplastic syndromes

Author(s): 
Lafargue MC, Duong Van Huyen JP, Rennke HG, Essig M, Bobot M, Jourde-Chiche N, Sakhi H, Karras A, Boudhabhay I, Brunet P, Boulay H, Grobost V, Philipponnet C, Jeannel J, Chemouny J, Boffa JJ, Braham-Stambouli D, Selamet U, Riella LV, Fain O, Adès L,
Primary Author: 
Lafargue MC
Journal Title: 
Clinical Kidney Journal
Original Publication Date: 
Jun 2024

Introduction: The objective of this study was to describe kidney involvement in patients with

Bone Marrow Disease(s): 

Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial

Author(s): 
Díez-Campelo M, López-Cadenas F, Xicoy B, Lumbreras E, González T, Del Rey González M, Sánchez-García J, Coll Jordà R, Slama B, Hernández-Rivas JÁ, Thepot S, Bernal T, Guerci-Bresler A, Bargay J, Amigo ML, Preudhomme C, Fenwarth L, Platzbecker U, Götze KS
Primary Author: 
Arar A, Toribio S, Del Cañizo C, Hernández-Rivas JM, Fenaux
Journal Title: 
Lancet Haematology
Original Publication Date: 
Jul 2024

Background: Lenalidomide is the standard of care for patients who are transfusion dependent with chromosome 5q deletion (del[5q])

Bone Marrow Disease(s): 

Patients' perspectives on oral decitabine/cedazuridine for the treatment of myelodysplastic syndromes/neoplasms

Author(s): 
Zeidan AM, Perepezko K, Salimi T, Washington T, Epstein RS
Primary Author: 
Zeidan AM
Journal Title: 
Therapeutic Advances in Hematology
Original Publication Date: 
Jul 2024

Background: Hypomethylating agents (HMAs) are guideline-recommended treatment for higher-risk

Bone Marrow Disease(s): 

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial

Author(s): 
Porta MGD, Garcia-Manero G, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcárcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Pilot R, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Prebet T, Lai Y, Degulys A, Paolini S, Cluzeau T
Primary Author: 
Porta MGD
Journal Title: 
Lancet Hematology
Original Publication Date: 
Jul 2024

Background: The preplanned interim analysis of the COMMANDS trial showed greater efficacy of luspatercept than epoetin alfa for treating anaemia in erythropoiesis-stimulating agent (ESA)-naive patients with transfusion-dependent, lower-risk

Bone Marrow Disease(s): 

Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation?

Author(s): 
Le Calvez B, Jullien M, Dalle JH, Renard C, Jubert C, Sterin A, Paillard C, Huynh A, Guenounou S, Bruno B, Gandemer V, Buchbinder N, Simon P, Pochon C, Sirvent A, Plantaz D, Kanold J, Béné MC, Rialland F, Grain A;
Primary Author: 
Le Calvez B
Journal Title: 
HemaSphere
Original Publication Date: 
Jul 2024

For most patients with childhood myelodysplastic syndrome (cMDS), allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative option. In the case of increased blasts (cMDS-IB), the benefit of pretransplant cytoreductive therapy remains controversial. In this multicenter retrospective study, the outcomes of all French children who underwent allo-HSCT for cMDS reported in the SFGM-TC registry between 2000 and 2020 were analyzed (n = 84).

Bone Marrow Disease(s): 

Molecular Taxonomy of Myelodysplastic Syndromes and its Clinical Implications

Author(s): 
Bernard E, Hasserjian RP, Greenberg PL, Arango Ossa JE, Creignou M, Tuechler H, Gutiérrez-Abril J, Domenico D, Medina-Martinez JS, Levine MF, Liosis K, Farnoud N, Sirenko M, Jädersten M, Germing U, Sanz GF, Van de Loosdrecht AA, Nannya Y, Kosmider O,
Primary Author: 
Bernard E
Journal Title: 
Blood
Original Publication Date: 
Jul 2024

Bone Marrow Disease(s):